SloveniaScientists have announced groundbreaking results from phase three clinical trials showing that a personalized mRNA therapy combined with existing immunotherapy significantly prevents the recurrence of melanoma more effectively than immunotherapy alone. The treatment targets microscopic cancer cells left behind after surgery by using a patient’s unique tumor mutation profile to create tailored mRNA therapy. This approach guides the immune system to specifically attack residual cancer cells, while the drug Keytruda removes immune system barriers to enhance the body’s response. Although promising, the therapy remains experimental and requires further data before regulatory approval.
Bias read (Center): The article discusses medical advancements in cancer treatment without taking a political stance or involving political figures, policies, or controversies. It focuses purely on scientific research and health outcomes.
